[go: up one dir, main page]

MX2024013311A - Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina - Google Patents

Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina

Info

Publication number
MX2024013311A
MX2024013311A MX2024013311A MX2024013311A MX2024013311A MX 2024013311 A MX2024013311 A MX 2024013311A MX 2024013311 A MX2024013311 A MX 2024013311A MX 2024013311 A MX2024013311 A MX 2024013311A MX 2024013311 A MX2024013311 A MX 2024013311A
Authority
MX
Mexico
Prior art keywords
sub
bcl
degraders
heterobifunctional
tetrahydroisoquinoline
Prior art date
Application number
MX2024013311A
Other languages
English (en)
Inventor
Evan J Horn
Joshua D Hansen
Matthew D Alexander
Fei Huang
Mark A Nagy
Original Assignee
Treeline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeline Biosciences Inc filed Critical Treeline Biosciences Inc
Publication of MX2024013311A publication Critical patent/MX2024013311A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta descripción proporciona compuestos de la Fórmula (I) o (II) (p. ej., Fórmula (I-A), (I-B), o (I-C)), o una sal farmacéuticamente aceptable de este, que inducen la degradación de una proteína BCL-XL. Estos compuestos son útiles, por ejemplo, para tratar un cáncer en un sujeto (p. ej., un ser humano). Esta descripción también proporciona composiciones que contienen los compuestos o sales farmacéuticamente aceptables de estos, como se proporcionan en la presente descripción, así como también métodos de uso y fabricación de los mismos.
MX2024013311A 2022-05-06 2024-10-28 Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina MX2024013311A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263339262P 2022-05-06 2022-05-06
US202263398769P 2022-08-17 2022-08-17
US202263429814P 2022-12-02 2022-12-02
US202363454477P 2023-03-24 2023-03-24
PCT/US2023/020987 WO2023215471A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Publications (1)

Publication Number Publication Date
MX2024013311A true MX2024013311A (es) 2025-02-10

Family

ID=86760567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013311A MX2024013311A (es) 2022-05-06 2024-10-28 Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina

Country Status (7)

Country Link
US (1) US20250282771A1 (es)
EP (1) EP4519260A1 (es)
JP (1) JP2025516358A (es)
AU (1) AU2023265886A1 (es)
CA (1) CA3256666A1 (es)
MX (1) MX2024013311A (es)
WO (1) WO2023215471A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101575A1 (en) * 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
TW202527930A (zh) * 2023-11-07 2025-07-16 美商樹線生物科學公司 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑
WO2025101571A1 (en) * 2023-11-07 2025-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8889675B2 (en) 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
JP7385284B2 (ja) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー 癌処置のためのｂｃｌ－２タンパク質分解剤
CN113660937A (zh) 2019-02-08 2021-11-16 佛罗里达大学研究基金公司 治疗剂和治疗方法
US20220265834A1 (en) 2019-07-10 2022-08-25 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
IL297586A (en) 2020-04-28 2022-12-01 Recurium Ip Holdings Llc bcl-2 protein inhibitors
US20240376094A2 (en) 2021-02-02 2024-11-14 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2023044046A1 (en) 2021-09-17 2023-03-23 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof

Also Published As

Publication number Publication date
WO2023215471A1 (en) 2023-11-09
EP4519260A1 (en) 2025-03-12
US20250282771A1 (en) 2025-09-11
AU2023265886A1 (en) 2024-11-07
CA3256666A1 (en) 2023-11-09
JP2025516358A (ja) 2025-05-27

Similar Documents

Publication Publication Date Title
MX2024013311A (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
CL2025001072A1 (es) Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer.
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
PA8596001A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ES2196377T3 (es) Derivados de naftiridina.
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
PA8680701A1 (es) Derivados de oxindol
CO2024010542A2 (es) Inhibidores de apol1 y métodos de uso
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2024011199A2 (es) Composiciones y métodos para inhibir el factor b del complemento
MX2024013312A (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
CY1115687T1 (el) Ενωσεις για θεραπεια ανικανοτητας
CO2025003263A2 (es) Inhibidores de kif18a y usos de estos
CO2021017202A2 (es) Compuestos tricíclicos
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
CR20250176A (es) Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y métodos de uso de los mismos
MX2025002817A (es) Compuestos para el tratamiento del cancer
CL2024003831A1 (es) Degradadores heterobifuncionales de bcl6 de 1,8-naftiridin-2-ona
DOP2025000009A (es) Inhibidores de acc novedosos
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso